LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
== Selected publications == Ammann AJ and Stiehm ER. Immune Globulin Levels in Colostrum and Breast Milk, and Serum From Formula- and Breast-Fed Newborns.[link removed] Proc Soc Exp Biol Med, 122:1098-1100, 1966. Stiehm ER, Ammann AJ, Cherry JD. Elevated cord macroglobulins in the diagnosis of intrauterine infections. NEJM, 275:971-977, 1966. Ammann AJ, Wara D, Salmon S, Perkins H. Thymus transplantation. Thymus Transplantation — Permanent Reconstitution of Cellular Immunity in a Patient with Sex-Linked Combined Immunodeficiency. NEJM, 289:5-9, 1973. Wara DW, Goldstein AL, Doyle NE, Ammann AJ. Thymosin Activity in Patients with Cellular Immunodeficiency. NEJM, 292:70-74, 1975. (One of the 500 most widely quoted articles in 1980, Citation Classic) Giblett ER, Ammann AJ, Sandman R, Wara DW, Diamond LK. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet, 1:2020-1014, 1975. (One of the 500 most widely quoted articles in 1984, Citation Classic) Ammann AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. NEJM, 297:897-900, 1977. Ammann AJ, Cowan MJ, Wara DW, Weintrub P, Dritz S, Goldman H, Perkins HA. Acquired immunodeficiency in an infant: Possible transmission by means of blood products. Lancet, 1:956-958, 1983.
=== Storage and disposal === The fentanyl patch is one of a few medications that may be especially harmful, and in some cases fatal, with just one dose, if misused by a child. In British Columbia, Canada, where there are environmental concerns about toilet flushing or garbage disposal, pharmacists recommend that unused patches be sealed in a child-proof container that is then returned to a pharmacy. In the United States, where patches cannot always be returned through a medication take-back program, flushing is recommended for fentanyl patches, because it is the fastest and surest way to remove them from the home, preventing ingestion by children, pets or others not intended to use them.
In in vitro kinetic experiments measuring OGT and OGA activity on a panel of protein substrates, kinetic parameters for OGT were shown to be variable between various proteins while kinetic parameters for OGA were relatively constant between various proteins. This result suggested that OGT is the "senior partner" in regulating O-GlcNAc and OGA primarily recognizes substrates via the presence of O-GlcNAc rather than the identity of the modified protein.
== History == Oxymorphone was first developed in Germany in 1914, and patented in the US by Endo Pharmaceuticals in 1955. It was introduced in the United States in January 1959 and other countries around the same time.
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7), blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.
Sources: en.wikipedia.org
Branched chain fatty acids are usually saturated and are found in two distinct families: the iso-series and anteiso-series. It has been found that Actinomycetales contain unique branch-chain fatty acid synthesis mechanisms, including that which forms tuberculostearic acid.
John D. Rockefeller Sr. first conceived the idea of the foundation in 1901. In 1906, Rockefeller's business and philanthropic advisor, Frederick Taylor Gates, encouraged him toward "permanent corporate philanthropies for the good of Mankind" so that his heirs should not "dissipate their inheritances or become intoxicated with power." In 1909 Rockefeller signed over 73,000 Standard Oil shares worth $50 million, to his son, Gates and Harold Fowler McCormick as the third inaugural trustee, in the first installment of a projected $100 million endowment. The nascent foundation applied for a federal charter in the US Senate in 1910, with at one stage Junior even secretly meeting with President William Howard Taft, through the aegis of Senator Nelson Aldrich, to hammer out concessions. However, because of the ongoing (1911) antitrust suit against Standard Oil at the time, along with deep suspicion in some quarters of undue Rockefeller influence on the spending of the endowment, the result was that Senior and Gates withdrew the bill from Congress in order to seek a state charter from New York.
microsatellite Also short tandem repeat (STR) or simple sequence repeat (SSR). A type of satellite DNA consisting of a relatively short sequence of tandem repeats, in which certain motifs (ranging in length from one to six or more bases) are repeated, typically 5–50 times. Microsatellites are widespread throughout most organisms' genomes and tend to have higher mutation rates than other regions. They are classified as variable number tandem repeat (VNTR) DNA, along with longer minisatellites.
== Applications == Some polyphenols are traditionally used as dyes in leather tanning. For instance, in the Indian subcontinent, pomegranate peel, high in tannins and other polyphenols, or its juice, is employed in the dyeing of non-synthetic fabrics. Of some interest in the era of silver-based photography, pyrogallol and pyrocatechin are among the oldest photographic developers.
Sources: en.wikipedia.org
=== Puerto Rican women === The history of sterilizations in the United States and Puerto Rico can be defined as an intersectional form of oppression that connects race, class, and sex to the social, political, and economic status of Puerto Ricans. The oppressive nature of these procedures lie within the fact that they were politically backed and used within the court of law against Puerto Ricans. Other women on the island experienced an increase in surveillance and control of their body within social realms. This illustrates how sterilizations were conducted on a continuum and had vast as well as long lasting consequences. In 1947, 7% of mothers aged 20–49 received tubal ligation which almost doubled in 1954 as sterilizations increased on the island to 16%. By 1965, over 34% of Puerto Rican women within this age bracket received sterilizations, which is five times the rate two decades prior. Sterilization was the most heavily promoted method of contraception in Puerto Rico and was legitimized by concerns of population, which can be associated with the same concerns of race and class that date back to the island's annexation. After the US gained ownership of Puerto Rico, it was viewed as a province in urgent need of a way to prevent greater poverty and population rates. This heavily influenced the US decision to begin sterilizing Puerto Rican women and implementing experimental birth control methods. Puerto Rican women in particular have served as test subjects for various contraceptive studies in the United States, of which included involuntary sterilization.
=== Steps === Lyse cells and prepare sample for immunoprecipitation. Pre-clear the sample by passing the sample over beads alone or bound to an irrelevant antibody to soak up any proteins that non-specifically bind to the IP components. Incubate solution with antibody against the protein of interest. Antibody can be attached to solid support before this step (direct method) or after this step (indirect method). Continue the incubation to allow antibody-antigen complexes to form. Precipitate the complex of interest, removing it from bulk solution. Wash precipitated complex several times. Spin each time between washes when using agarose beads or place tube on magnet when using superparamagnetic beads and then remove the supernatant. After the final wash, remove as much supernatant as possible. Elute proteins from the solid support using low-pH or SDS sample loading buffer. Analyze complexes or antigens of interest. This can be done in a variety of ways: SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) followed by gel staining. SDS-PAGE followed by: gel staining, cutting out individual stained protein bands, and sequencing the proteins in the bands by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. Transfer and Western blot using another antibody for proteins that were interacting with the antigen, followed by detection using a chemiluminescent or fluorescent secondary antibody.
== Further reading == B.L. Karger, 2014, "Separation and Purification: Single-stage versus multistage processes" and "Separation and Purification: Separations Based on Equilibrium", Encyclopædia Britannica, see [1] and [2], accessed 12 May 2014. Gunt Hamburg, 2014, "Thermal Process Engineering: liquid–liquid extraction and solid-liquid extraction", see [3], accessed 12 May 2014. G.W. Stevens, T.C., Lo, & M. H. I. Baird, 2007, "Extraction, liquid–liquid", in Kirk-Othmer Encyclopedia of Chemical Technology, doi:10.1002/0471238961.120917211215.a01.pub2, accessed 12 May 2014. Colin Poole & Michael Cooke, 2000, "Extraction", in Encyclopedia of Separation Science, 10 Vols., ISBN 978-0-12-226770-3, see [4], accessed 12 May 2014. Sikdar, Cole, et al. Aqueous Two-Phase Extractions in Bioseparations: An Assessment. Biotechnology 9:254. 1991 Szlag, Giuliano. A Low-Cost Aqueous Two Phase System for Enzyme Extraction. Biotechnology Techniques 2:4:277. 1988 Dreyer, Kragl. Ionic Liquids for Aqueous Two-Phase Extraction and Stabilization of Enzymes. Biotechnology and Bioengineering. 99:6:1416. 2008 Boland. Aqueous Two-Phase Systems: Methods and Protocols. Pg 259-269 https://web.archive.org/web/20100702074135/http://ull.chemistry.uakron.edu/chemsep/extraction/ Topological Analysis of the Gibbs Energy Function (Liquid-Liquid Equilibrium Correlation Data). Including a Thermodynamic Review and a Graphical User Interface (GUI) for Surfaces/Tie-lines/Hessian matrix analysis - University of Alicante (Reyes-Labarta et al. 2015-18)
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.